1 week Ago By ABMN Staff
Needham & Company LLC reaffirmed their buy rating on shares of Liquidia ( NASDAQ:LQDA – Free Report ) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.
Several other equities analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th.
Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.
00 target price for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.
com, Liquidia presently has a consensus rating of “Buy” and an average target price of $26.63. Read Our Latest Research Report on LQDA Liquidia Stock Performance Liquidia ( NASDAQ:LQDA – Get Free Report ) last released its earnings results on Wednesday, March 19th.
The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.
08). The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.
60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.
38%. On average, equities analysts predict that Liquidia will post -1.51 EPS for the current fiscal year.
Insider Transactions at Liquidia In other news, General Counsel Russell Schundler sold 16,393 shares of Liquidia stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.
54. Following the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84.
The trade was a 2.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link .
Also, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.
00. Following the completion of the transaction, the insider now owns 267,943 shares of the company’s stock, valued at $3,483,259. The trade was a 0.
90 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold a total of 71,245 shares of company stock worth $843,326 in the last quarter.
Company insiders own 30.10% of the company’s stock. Hedge Funds Weigh In On Liquidia Several large investors have recently modified their holdings of LQDA.
Vanguard Group Inc. increased its position in shares of Liquidia by 3.4% during the 4th quarter.
Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after purchasing an additional 115,367 shares during the last quarter. LM Advisors LLC acquired a new stake in shares of Liquidia during the fourth quarter valued at about $25,948,000.
Whitefort Capital Management LP raised its stake in shares of Liquidia by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after acquiring an additional 285,220 shares during the period.
Vestal Point Capital LP lifted its holdings in shares of Liquidia by 17.3% in the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock worth $20,698,000 after acquiring an additional 260,000 shares during the last quarter.
Finally, Geode Capital Management LLC lifted its holdings in shares of Liquidia by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock worth $15,753,000 after acquiring an additional 101,597 shares during the last quarter.
Institutional investors and hedge funds own 64.54% of the company’s stock. About Liquidia ( Get Free Report ) Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). See Also Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter .
.
